May 25, 2016
Shionogi said on May 24 that its peripherally-acting mu-opioid receptor antagonist naldemedine, which is being developed for opioid-induced constipation (OIC), demonstrated consistent efficacy and safety in treating OIC in patients with chronic non-cancer pain in global PIII studies. In two...read more